February 2023

Entesitis del Tendón Calcáneo en el Examen Físico Lleva a Desenlaces Peores Después de 2 Años de Seguimiento en Pacientes con Espondilitis Anquilosante del Registro REGISPONSER-AS

Arthritis Res Ther. doi: 10.1186/s13075-023-02988-x

The results highlighted the long-term impact of the presence of Achilles enthesitis on the burden of disease. The objectives of this study were to evaluate the impact of Achilles' tendon enthesitis found at baseline during physical examination on the outcome measures after 2 years of follow-up in patients with AS.

Keywords:

Eficacia y Seguridad de Bimekizumab en las Espondiloartritis Axiales: Resultados de Dos Ensayos Paralelos de Fase 3 Aleatorizados y Controlados

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

El efecto de Guselkumab en la Inhibición Radiográfica en Pacientes con Artritis Psoriásica Activa: Protocolo del Estudio APEX, un ensayo de Fase 3b, Multicéntrico, Aleatorizado, Doble-ciego, Controlado con Placebo

Trials. 2023 doi: 10.1186/s13063-022-06945-y

Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Keywords:

Herpes Zoster en Pacientes con Artritis Inflamatorias o Colitis Ulcerosa Tratados con Tofacitinib, Baricitinib o Upadacitinib: Una Revisión Sistemática de Estudios Clínicos y Estudios de Mundo Real

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.

Keywords:

Inhibición selectiva de la vía MK2: Datos de un Ensayo de Fase II Aleatorizado Controlado en Artritis Reumatoide

ACR Open Rheumatol. 2023;5(2):63–70 doi: 10.1002/acr2.11517

Data show that the first-in-class MK2 pathway inhibitor ATI-450 was well tolerated and induced sustained anti-inflammatory efficacy over 12 weeks in patients with moderate-to-severe RA.

Keywords:

January 2023

Seguridad y Eficacia de Bimekizumab en Pacientes con Espondilitis Anquilosante Activa: resultados de tres años de un estudio de fase IIb aleatorizado controlado y su estudio de extensión abierto

Arthritis Rheumatol. 2022;74:1943–58

In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Keywords:

Eficacia y seguridad de Bimekizumab en pacientes con Artritis Psoriásica Activa: Resultados de Tres Años de un Estudio de Fase IIb Aleatorizado Controlado y su Estudio de Extensión Abierto

Arthritis Rheumatol. 2022 doi: 10.1002/art.42280

This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.

Keywords:

Bimekizumab en Pacientes con Artritis Psoriásica Activa y Respuesta Previa Inadecuada o Intolerancia a Inhibidores de Factor de Necrosis Tumoral-α: Un Ensayo clínico de fase 3, aleatorizado, doble ciego y controlado con placebo (BE COMPLETE)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0

This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.

Keywords:

Bimekizumab en Pacientes con Artritis Psoriásica naive a una terapia biológica: Un ensayo de fase 3 aleatorizado, doble ciego, placebo-controlado (BE OPTIMAL)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9

This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.

Keywords:

¿Pueden los pacientes con artritis reumatoide controlada reducir la dosis de metotrexato de la terapia dirigida y mantener la remisión? Una Revisión Sistemática y Metaanálisis

J Rheumatol. 2023;50(1):36–47 doi: 10.3899/jrheum.220152

This systematic review and meta-analysis of studies evaluated the proportion of patients in remission after the dosage of MTX was tapered, and concludes that patients with controlled RA may taper MTX from targeted therapy with a 10% reduction in the ability to sustain remission for up to 18 months.

Keywords: